Literature DB >> 10933702

Poxvirus-induced immunostimulating effects on porcine leukocytes.

V Fachinger1, T Schlapp, W Strube, N Schmeer, A Saalmüller.   

Abstract

The prophylactic application of inactivated parapox ovis viruses (Baypamun; Bayer AG, Leverkusen, Germany) has been shown to reduce efficiently the outbreak of stress-mediated diseases in different species. However, little is known about the basic mechanism behind this observed stimulatory property. We therefore tested eight inactivated poxvirus strains belonging to three different genera (Orthopoxvirus, Avipoxvirus, and Parapoxvirus) for their capacity to activate cells of the porcine innate and specific immune systems in vitro. The results indicated that poxviruses failed to induce increased phagocytosis, oxidative burst, or natural killer cell activity in swine. In contrast, enhanced release of interleukin-2, alpha interferon, and gamma interferon, as well as strong proliferation, could be measured. Flow cytometric analyses and cell sorting experiments identified T-helper cells as the main target responding to inactivated poxviruses: the activated cells had a CD4(high) CD25(+) major histocompatibility complex type II-positive phenotype and were the major source of secreted cytokines. Together, the results demonstrated that all tested poxviruses possessed immunostimulating capacity. These in vitro poxvirus-induced effects may be responsible at least in part for the in vivo immunostimulating capacity of inactivated poxviruses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933702      PMCID: PMC112325          DOI: 10.1128/jvi.74.17.7943-7951.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  [Comparative studies of the immunostimulating (paramunizing) effectiveness of BCG, levamisole, Corynebacterium parvum and preparations of pock viruses in various in vivo and in vitro tests].

Authors:  A Mayr; M Büttner; S Pawlas; V Erfle; B Mayr; R Brunner; K Osterkorn
Journal:  Zentralbl Veterinarmed B       Date:  1986-06

2.  Convenient assay for interferons.

Authors:  S Rubinstein; P C Familletti; S Pestka
Journal:  J Virol       Date:  1981-02       Impact factor: 5.103

3.  [Control of ecthyma contagiosum (pustular dermatitis) of sheep with a new parenteral cell culture live vaccine].

Authors:  A Mayr; M Herlyn; H Mahnel; A Danco; A Zach; H Bostedt
Journal:  Zentralbl Veterinarmed B       Date:  1981

4.  [Nonspecific prophylaxis and therapy of Pseudomonas aeruginosa wound-infections with paramunization using a mouse-model (author's transl)].

Authors:  A Mayr; B Himmer; G Baljer; J Sailer
Journal:  Zentralbl Bakteriol Orig A       Date:  1979-09

5.  A monoclonal antibody recognising an epitope associated with pig interleukin-2 receptors.

Authors:  M Bailey; K Stevens; P W Bland; C R Stokes
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

6.  A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection.

Authors:  A Alcamí; G L Smith
Journal:  Cell       Date:  1992-10-02       Impact factor: 41.582

7.  Encoding of a homolog of the IFN-gamma receptor by myxoma virus.

Authors:  C Upton; K Mossman; G McFadden
Journal:  Science       Date:  1992-11-20       Impact factor: 47.728

8.  Murine anti-swine T4 and T8 monoclonal antibodies: distribution and effects on proliferative and cytotoxic T cells.

Authors:  M D Pescovitz; J K Lunney; D H Sachs
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  Characterization of monoclonal antibodies directed against swine leukocytes.

Authors:  C Hammerberg; G G Schurig
Journal:  Vet Immunol Immunopathol       Date:  1986-02       Impact factor: 2.046

10.  Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation.

Authors:  H W Murray; Z A Cohn
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

View more
  13 in total

1.  ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

Authors:  Julia L Rintoul; Chantal G Lemay; Lee-Hwa Tai; Marianne M Stanford; Theresa J Falls; Christiano T de Souza; Byram W Bridle; Manijeh Daneshmand; Pamela S Ohashi; Yonghong Wan; Brian D Lichty; Andrew A Mercer; Rebecca C Auer; Harold L Atkins; John C Bell
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

2.  Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer.

Authors:  Audrey H Choi; Michael P O'Leary; Shyambabu Chaurasiya; Jianming Lu; Sang-In Kim; Yuman Fong; Nanhai G Chen
Journal:  Surgery       Date:  2017-11-22       Impact factor: 3.982

3.  A novel inhibitor of the NF-{kappa}B signaling pathway encoded by the parapoxvirus orf virus.

Authors:  D G Diel; G Delhon; S Luo; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice.

Authors:  Timo Fischer; Oliver Planz; Lothar Stitz; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

6.  Novel immune-modulator identified by a rapid, functional screen of the parapoxvirus ovis (Orf virus) genome.

Authors:  Michael J McGuire; Stephen A Johnston; Kathryn F Sykes
Journal:  Proteome Sci       Date:  2012-01-13       Impact factor: 2.480

7.  Modulation of macrophage functions by sheeppox virus provides clues to understand interaction of the virus with host immune system.

Authors:  Abdel-Aziz S Abu-El-Saad; Ahmed S Abdel-Moneim
Journal:  Virol J       Date:  2005-03-22       Impact factor: 4.099

8.  Equine PBMC Cytokines Profile after In Vitro α- and γ-EHV Infection: Efficacy of a Parapoxvirus Ovis Based-Immunomodulator Treatment.

Authors:  Erika S Hue; Eric A Richard; Christine I Fortier; Guillaume D Fortier; Romain Paillot; Rudiger Raue; Stéphane L Pronost
Journal:  Vaccines (Basel)       Date:  2017-09-19

Review 9.  Therapeutic immunomodulation using a virus--the potential of inactivated orf virus.

Authors:  O Weber; A A Mercer; A Friebe; P Knolle; H-D Volk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-22       Impact factor: 5.103

10.  Inactivated Parapoxvirus ovis induces a transient increase in the expression of proinflammatory, Th1-related, and autoregulatory cytokines in mice.

Authors:  D Anziliero; R Weiblen; L C Kreutz; F Spilki; E F Flores
Journal:  Braz J Med Biol Res       Date:  2014-01-17       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.